Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of Thyroid Cancer in Children, Adolescents and Young Adults with Hashimoto Thyroiditis: a 27 Years Follow-up Study.

Hormone research in paediatrics·2026
Same author

Addison's disease in Italy: mortality and survival by etiology.

Journal of endocrinological investigation·2026
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same author

Pituitary adenoma imaging as a determinant of acromegaly diagnosis and outcomes.

The Journal of clinical endocrinology and metabolism·2026
Same author

Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.

Pituitary·2026
Same author

What is the future of acromegaly therapy?

The Journal of clinical endocrinology and metabolism·2026

Related Experiment Video

Updated: Jul 10, 2026

An Invasive Method for the Activation of the Mouse Dentate Gyrus by High-frequency Stimulation
12:26

An Invasive Method for the Activation of the Mouse Dentate Gyrus by High-frequency Stimulation

Published on: June 2, 2018

Pegvisomant-primed GH stimulation test.

Giorgio Radetti1, Zida Wu, Heba H Elsedfy

  • 1Department of Paediatrics, Regional Hospital of Bolzano, Bolzano, Italy. giorgio.radetti@asbz.it

Clinical Endocrinology
|November 23, 2007
PubMed
Summary

Pegvisomant priming improved growth hormone (GH) testing reliability in short children. This method helps unmask false-positive results, enhancing diagnostic accuracy for potential GH deficiency.

More Related Videos

Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma
11:02

Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma

Published on: August 9, 2022

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats
09:36

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats

Published on: March 23, 2022

Related Experiment Videos

Last Updated: Jul 10, 2026

An Invasive Method for the Activation of the Mouse Dentate Gyrus by High-frequency Stimulation
12:26

An Invasive Method for the Activation of the Mouse Dentate Gyrus by High-frequency Stimulation

Published on: June 2, 2018

Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma
11:02

Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma

Published on: August 9, 2022

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats
09:36

In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats

Published on: March 23, 2022

Area of Science:

  • Pediatric Endocrinology
  • Growth Hormone Physiology

Background:

  • Growth hormone (GH) assessment via provocative stimulation tests often lacks reproducibility and yields false positives in children.
  • Accurate diagnosis of GH deficiency is crucial for appropriate treatment and management.

Purpose of the Study:

  • To evaluate pegvisomant's efficacy in enhancing GH secretion and unmasking false-positive GH test results in short children.
  • To improve the diagnostic reliability of GH testing.

Main Methods:

  • A prospective study involved 21 short children undergoing L-DOPA stimulation tests for GH assessment.
  • Pegvisomant was administered subcutaneously after the initial test, followed by a repeat L-DOPA stimulation test three days later.

Main Results:

  • Pegvisomant administration led to a significant decrease in Insulin-like Growth Factor-I Standard Deviation Scores (IGF-I SDS) and a significant increase in peak GH levels.
  • Following pegvisomant priming, 55.5% of children initially showing insufficient GH response demonstrated normal secretion, while 44.5% still had confirmed insufficient secretory reserve.

Conclusions:

  • Pegvisomant priming can enhance the diagnostic accuracy of GH stimulation tests in evaluating short children.
  • Further research is needed to determine if this pegvisomant priming protocol should be integrated into routine GH deficiency diagnostics.